Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011104 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Atsuhiko Hasegawa und 13 weiteren Autor:innen. Beteiligte Einrichtung: Deparment of Immunotherapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, Leukemia-Lymphoma, Adult T-Cell, Simian T-lymphotropic virus 1, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japan Cancer Society.
Abstract (Originalsprache)
A small proportion of human T-cell leukemia virus type-1 (HTLV-1)-infected individuals develop adult T-cell leukemia/lymphoma, a chemotherapy-resistant lymphoproliferative disease with a poor prognosis. HTLV-1-specific cytotoxic T lymphocytes (CTLs), potential anti-tumor/virus effectors, are impaired in adult T-cell leukemia/lymphoma patients. Here, using Japanese monkeys naturally infected with simian T-cell leukemia/T-lymphotropic virus type-1 (STLV-1) as a model, we demonstrate that short-term-cultured autologous peripheral blood mononuclear cells (PBMCs) can serve as a therapeutic vaccine to activate such CTLs. In a screening test, STLV-1-specific CTL activity was detectable in 8/10 naturally STLV-1-infected monkeys. We conducted a vaccine study in the remaining two monkeys with impaired CTL responses. The short-term-cultured PBMCs of these monkeys spontaneously expressed viral antigens, in a similar way to PBMCs from human HTLV-1 carriers. The first monkey was subcutaneously inoculated with three-day-cultured and mitomycin C (MMC)-treated autologous PBMCs, and then boosted with MMC-treated autologous STLV-1-infected cell line cells. The second monkey was inoculated with autologous PBMC-vaccine alone twice. In addition, a third monkey that originally showed a weak STLV-1-specific CTL response was inoculated with similar autologous PBMC-vaccines. In all three vaccinated monkeys, marked activation of STLV-1-specific CTLs and a mild reduction in the STLV-1 proviral load were observed. Follow-up analyses on the two monkeys vaccinated with PBMCs alone indicated that STLV-1-specific CTL responses peaked at 3–4 months after vaccination, and then diminished but remained detectable for more than one year. The significant reduction in the proviral load and the control of viral expression were associated with CTL activation but also diminished 6 and 12 months after vaccination, respectively, suggesting the requirement for a booster. The vaccine-induced CTLs in these monkeys recognized epitopes in the STLV-1 Tax and/or Envelope proteins, and efficiently killed autologous STLV-1-infected cells in vitro . These findings indicated that the autologous PBMC-based vaccine could induce functional STLV-1-specific CTLs in vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Deparment of Immunotherapeutics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Cancer Cell Biology Laboratory, Department of Cancer Biology, Clinical Research Institute, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Japan.
- Center for the Evolutionary Origins of Human Behavior, Kyoto University, Kyoto, Japan.
- Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases, Tokyo, Japan.
- Department of Microbiology, Kansai Medical University, Osaka, Japan.
ORCID-Profile: Mari Kannagi
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- Japan Cancer Society
Zitieren
APA
Hasegawa, A., Murata, M., Fujikawa, T., Katagiri, K., Nagano, Y., Masuda, T., Kuramitsu, M., Nakajima, S., Fujisawa, J. I., Okuma, K., Grover, P., Kidiga, M., Akari, H., & Kannagi, M. (2023). Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011104
Vancouver
Hasegawa A, Murata M, Fujikawa T, Katagiri K, Nagano Y, Masuda T, et al. Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011104
BibTeX
@article{Hasegawa2023,
author = {Hasegawa, Atsuhiko and Murata, Megumi and Fujikawa, Tomoka and Katagiri, Kuniko and Nagano, Yoshiko and Masuda, Takao and Kuramitsu, Madoka and Nakajima, Shinsuke and Fujisawa, Jun-Ichi and Okuma, Kazu and Grover, Poonam and Kidiga, Maureen and Akari, Hirofumi and Kannagi, Mari},
title = {Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011104}
}
EUVIMED